ReviewPolymers2023
Human Serum Albumin Based Nanodrug Delivery Systems: Recent Advances and Future Perspective.
Review in Polymers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- The colloidal stability of albumin-based drug delivery systems has a profound effect on tumoricidal activity.Drug delivery · 2026Article
- Imaging-guided COX-2 inhibition synergizes with photodynamic immunogenic cell death to potentiate checkpoint blockade in colon cancer.International journal of pharmaceutics: X · 2026Article
- Serum-Integrated Dopamine-Hyaluronic Acid Hydrogels for Injectable Soft-Tissue Microenvironment Modulation.Macromolecular bioscience · 2026Article
- Engineering intrinsically radiolabeled nanoparticles for imaging and therapy: a decade of design strategies and insights.RSC advances · 2026Review
- Protein-Based Nanomaterials for Cancer Therapy: A Comparative and Translational Perspective.Pharmaceutics · 2026Review
- Gaining Insights Into the Formation of the Cathepsin B Inhibitor II-Human Serum Albumin Complex: A Multidisciplinary Approach.Luminescence : the journal of biological and chemical luminescence · 2026Article
- Generative Artificial Intelligence Optimization of Albumin Binders: Coumarin and Fatty Acid Derivatives.Journal of chemical information and modeling · 2026Article
- Targeted inhibition of ATP synthase subunit c by pp10-loaded inhalable albumin nanoparticles ameliorates airway inflammation in asthma.Journal of nanobiotechnology · 2026Article
- Lutein Modulates Stress-Responsive Signaling Pathways in THLE-2 Human Hepatocytes Under Intestinal Failure-Associated Liver Disease Conditions.Molecules (Basel, Switzerland) · 2026Article
- A Degradable Nanosystem Based on Small Gold Nanoparticles and Albumin for Amyloid Aggregation Inhibition.Pharmaceutics · 2026Article
- Unravelling the Interaction Mechanism Between Oryzanol and Human Serum Albumin: An Integrated Approach Using Multispectral Analysis and Molecular Simulations.Foods (Basel, Switzerland) · 2026Article
- Albumin Nanoparticle-Based Delivery of Oxaliplatin-Oleic Acid Prodrug for Enhanced Breast Cancer Therapy.AAPS PharmSciTech · 2026Article
- Development of a Prophylactic mRNA Vaccine for Severe Fever with Thrombocytopenia Syndrome Using HSA based LNP.NPJ vaccines · 2026Article
- A Human β-Defensin-Based Recombinant Protein DFCells · 2026Article
- Development of Human Serum Albumin-Based Hydrogels for Potential Use as Wound Dressings.Gels (Basel, Switzerland) · 2026Article
- Transforming RNA-Based Gene Therapy with Innovative Nanocarriers for siRNA and miRNA Delivery.Current gene therapy · 2026Review
- Article
- Advancing Lung Cancer Treatment: A Comprehensive Review of Photodynamic Therapy and Nanoparticle Applications.Pharmaceutics · 2025Review
- Functionalized albumin nanoparticles: A multifunctional platform for enhanced brain drug delivery.Materials today. Bio · 2025Review
- Human Serum Albumin-Based Nanoparticles for Targeted Intracellular Drug Delivery.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
With the success of several clinical trials of products based on human serum albumin (HSA) and the rapid development of nanotechnology, HSA-based nanodrug delivery systems (HBNDSs) have received extensive attention in the field of nanomedicine. However, there is still a lack of comprehensive reviews exploring the broader scope of HBNDSs in biomedical applications beyond cancer therapy. To address this gap, this review takes a systematic approach. Firstly, it focuses on the crystal structure and the potential binding sites of HSA. Additionally, it provides a comprehensive summary of recent progresses in the field of HBNDSs for various biomedical applications over the past five years, categorized according to the type of therapeutic drugs loaded onto HSA. These categories include small-molecule drugs, inorganic materials and bioactive ingredients. Finally, the review summarizes the characteristics and current application status of HBNDSs in drug delivery, and also discusses the challenges that need to be addressed for the clinical transformation of HSA formulations and offers future perspectives in this field.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.